BioVaxys Technology Corp.

08:35 AM EST - BioVaxys Technology Corp. : Announced today that it has filed with the United States Patent & Trademark Office a provisional patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses, the family of Coronaviruses that includes SARS-CoV-2, which causes Covid-19. BioVaxys Technology Corp. shares C.BIOV are trading unchanged at $0.35.

Stocks in Play